Reduced‐dose bacillus Calmette‐Guérin (BCG) in an era of BCG shortage: real‐world experience from a tertiary cancer centre-Reference-Cited by-同舟云学术

Reduced‐dose bacillus Calmette‐Guérin (BCG) in an era of BCG shortage: real‐world experience from a tertiary cancer centre

Published:2021-12-13 Issue: Volume: Page:
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Lobo Niyati¹^ORCID,Bree Kelly K.¹,Hensley Patrick J.¹^ORCID,Nogueras‐Gonzalez Graciela M.²,Abraham Prasanth¹,Navai Neema¹,Dinney Colin P.¹,Kamat Ashish M.¹

Affiliation:

1. Department of Urology University of Texas MD Anderson Cancer Center Houston TXUSA

2. Department of Biostatistics University of Texas MD Anderson Cancer Center Houston TX USA

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15661

Reference24 articles.

1. Intravesical bacillus Calmette‐Guerin versus mitomycin C for superficial bladder cancer: a formal meta‐analysis of comparative studies on recurrence and toxicity;Bohle A;J Urol,2003

2. Intravesical bacillus Calmette‐Guerin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials;Shelley MD;BJU Int,2004

3. Can intravesical bacillus Calmette‐Guerin reduce recurrence in patients with superficial bladder cancer? A meta‐analysis of randomized trials;Han RF;Urology,2006

4. An individual patient data meta‐analysis of the long‐term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette‐Guerin for non‐muscle‐invasive bladder cancer;Malmstrom PU;Eur Urol,2009

5. Intravesical bacillus Calmette‐Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta‐analysis of the published results of randomized clinical trials;Sylvester RJ;J Urol,2002

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non–Muscle-Invasive Bladder Cancer;JAMA Oncology;2024-04-01

2. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer;Future Oncology;2024-01-08

3. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study;Investigative and Clinical Urology;2024

4. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile;Bladder Cancer;2023-12-13

5. BCG infection dose guides dendritic cell migration and T cell priming in the draining lymph node;Scandinavian Journal of Immunology;2023-11-21